Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

Certain embodiments describe antiviral compounds and related methods of using such compounds.

Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

A process for producing 2-(2,2,6,6-tetramethylpiperidin-4-yl)propane-1,3-diamine by A) reacting triacetonamine (TAA) and malononitrile to afford the intermediate 2-(2,2,6,6-tetramethylpiperidin-4-ylidene)malononitrile, and B) hydrogenating 2-(2,2,6,6-tetramethylpiperidin-4-ylidene)malononitrile in the presence of at least one catalyst. In another embodiment, the hydrogenation in step B) of the process is performed at 20-120° C. and at 20-300 bar. In another embodiment, the hydrogenation in step B) of the process is performed in two stages at 20-120° C. and at 20-300 bar.

A process for producing 2-(2,2,6,6-tetramethylpiperidin-4-yl)propane-1,3-diamine by A) reacting triacetonamine (TAA) and malononitrile to afford the intermediate 2-(2,2,6,6-tetramethylpiperidin-4-ylidene)malononitrile, and B) hydrogenating 2-(2,2,6,6-tetramethylpiperidin-4-ylidene)malononitrile in the presence of at least one catalyst. In another embodiment, the hydrogenation in step B) of the process is performed at 20-120° C. and at 20-300 bar. In another embodiment, the hydrogenation in step B) of the process is performed in two stages at 20-120° C. and at 20-300 bar.

A method is disclosed for synthesizing a zeolite having the framework structure of SSZ-16 using a structure directing agent comprising a dication selected from one or more of 1,1′-(1,4-cyclohexylenedimethylene)bis[1-methylpiperidinium]; 1,1′-(1,4-cyclohexylenedimethylene)bis[1-ethylpiperidinium]; 1,1′-(1,4-cyclohexylenedimethylene)bis[1-methylpyrrolidinium]; and 1,1′-(1,4-cyclohexylenedimethylene)bis[1-ethylpyrrolidinium].

A method is disclosed for synthesizing a zeolite having the framework structure of SSZ-16 using a structure directing agent comprising a dication selected from one or more of 1,1′-(1,4-cyclohexylenedimethylene)bis[1-methylpiperidinium]; 1,1′-(1,4-cyclohexylenedimethylene)bis[1-ethylpiperidinium]; 1,1′-(1,4-cyclohexylenedimethylene)bis[1-methylpyrrolidinium]; and 1,1′-(1,4-cyclohexylenedimethylene)bis[1-ethylpyrrolidinium].

The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII:

##STR00001##

wherein A, B, X, Y, L.sup.1, L.sup.2, L.sup.3, R.sup.1, R.sup.2, R.sup.3, R.sup.4 R.sup.5, R.sup.6, R.sup.9, z.sup.2, z.sup.4, z.sup.5, and z.sup.6 are as defined herein, and salts thereof.

The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer’s disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington’s disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.